Cargando…
Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306721/ https://www.ncbi.nlm.nih.gov/pubmed/34984836 http://dx.doi.org/10.1002/dta.3214 |
_version_ | 1784752604557869056 |
---|---|
author | Czerwinska, Joanna Parkin, Mark C. George, Claire Kicman, Andrew T. Dargan, Paul I. Abbate, Vincenzo |
author_facet | Czerwinska, Joanna Parkin, Mark C. George, Claire Kicman, Andrew T. Dargan, Paul I. Abbate, Vincenzo |
author_sort | Czerwinska, Joanna |
collection | PubMed |
description | Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated 100 mg of pure mephedrone hydrochloride (Day 1). Urine was collected at different timepoints on Day 1 and then on Days 2, 3 and 30. Samples were analysed for the presence of mephedrone and its metabolites, namely, dihydro‐mephedrone, nor‐mephedrone (NOR), hydroxytolyl‐mephedrone, 4‐carboxy‐mephedrone (4‐carboxy) and dihydro‐nor‐mephedrone (DHNM), by a validated liquid chromatography‐tandem mass spectrometry method. All analytes were detected in urine, where 4‐carboxy (C(max) = 29.8 μg/ml) was the most abundant metabolite followed by NOR (C(max) = 377 ng/ml). DHNM was found at the lowest concentrations (C(max) = 93.1 ng/ml). Analytes exhibited a wide range of detection windows, but only 4‐carboxy and DHNM were detectable in all samples on Day 3, extending the detection time of mephedrone use. Moreover, mephedrone had a mean renal clearance of 108 ± 140 ml/min, and 1.3 ± 1.7% of unchanged parent drug was recovered in urine in the first 6 h post administration. It is hoped that this novel information will be useful in future studies involving mephedrone and other stimulant drugs. |
format | Online Article Text |
id | pubmed-9306721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93067212022-07-28 Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers Czerwinska, Joanna Parkin, Mark C. George, Claire Kicman, Andrew T. Dargan, Paul I. Abbate, Vincenzo Drug Test Anal Short Communications Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated 100 mg of pure mephedrone hydrochloride (Day 1). Urine was collected at different timepoints on Day 1 and then on Days 2, 3 and 30. Samples were analysed for the presence of mephedrone and its metabolites, namely, dihydro‐mephedrone, nor‐mephedrone (NOR), hydroxytolyl‐mephedrone, 4‐carboxy‐mephedrone (4‐carboxy) and dihydro‐nor‐mephedrone (DHNM), by a validated liquid chromatography‐tandem mass spectrometry method. All analytes were detected in urine, where 4‐carboxy (C(max) = 29.8 μg/ml) was the most abundant metabolite followed by NOR (C(max) = 377 ng/ml). DHNM was found at the lowest concentrations (C(max) = 93.1 ng/ml). Analytes exhibited a wide range of detection windows, but only 4‐carboxy and DHNM were detectable in all samples on Day 3, extending the detection time of mephedrone use. Moreover, mephedrone had a mean renal clearance of 108 ± 140 ml/min, and 1.3 ± 1.7% of unchanged parent drug was recovered in urine in the first 6 h post administration. It is hoped that this novel information will be useful in future studies involving mephedrone and other stimulant drugs. John Wiley and Sons Inc. 2022-01-11 2022-04 /pmc/articles/PMC9306721/ /pubmed/34984836 http://dx.doi.org/10.1002/dta.3214 Text en © 2022 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communications Czerwinska, Joanna Parkin, Mark C. George, Claire Kicman, Andrew T. Dargan, Paul I. Abbate, Vincenzo Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers |
title | Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers |
title_full | Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers |
title_fullStr | Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers |
title_full_unstemmed | Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers |
title_short | Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers |
title_sort | excretion of mephedrone and its phase i metabolites in urine after a controlled intranasal administration to healthy human volunteers |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306721/ https://www.ncbi.nlm.nih.gov/pubmed/34984836 http://dx.doi.org/10.1002/dta.3214 |
work_keys_str_mv | AT czerwinskajoanna excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers AT parkinmarkc excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers AT georgeclaire excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers AT kicmanandrewt excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers AT darganpauli excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers AT abbatevincenzo excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers |